Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: Results of phase II study

Lupus Science and Medicine

Volumn 2, Issue 1, 2015, Pages

  Urowitz, Murray B ^a   Isenberg, David A ^b   Wallace, Daniel J ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDRATIDE; PLACEBO;

ADULT; ALLERGY; ARTHRALGIA; ARTICLE; BACKACHE; COHORT ANALYSIS; COUGHING; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; ECZEMA; FEMALE; HEART PALPITATION; HERPES SIMPLEX; HUMAN; HYPERTENSION ENCEPHALOPATHY; HYPERTENSIVE CRISIS; HYPESTHESIA; INJECTION SITE REACTION; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; PAROXYSMAL TACHYCARDIA; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCIATICA; SEASONAL ALLERGY; SIDE EFFECT; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TREND STUDY; UPPER ABDOMINAL PAIN; URTICARIA; VAGINA MYCOSIS; VERTIGO; WEIGHT GAIN;

EID: 84949230365     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2015-000104     Document Type: Article

References (31)

1. Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. 5th edition. 1993:69-76.
2. Nagy G, Koncz A, Perl A. T and B cell abnormalities in systemic lupus erythematous. Crit Rev Immunol 2005;25:123-40.
3. Trebeden-Negre H, Weill B, Fournier C, et al. B cell aptosis accelerates the onset of murine lupus. Eur J Immunol 2003;33:1603-12.
4. Navratil JS, Ahearn JM. Apoptosis, clearance mechanisms, and the development of systemic lupus erythematosus. Curr Rheumatol Rep 2001;3:191-8.
5. Horowitz DA, Jacob CO. The cytokine network in the pathogenesis of systemic lupus. Semin Immunopathol 1994;16:181-200.
6. Dean GS, Tyrrell-Price J, Crawley E, et al. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000;59:243-51.
7. Paust S, Cantor H. Regulatory T cells and autoimmune disease. Immunol Rev 2005;204:195-207.
8. Sakaguchi S, Yamaguchi T, Nomuta T, et al. Regulatory T cells and immune tolerance. Cell 2008;133:775-87.
9. Eisenberg R. Why can't we find a new treatment for SLE? 2009;32:223-30.
10. Haubitz M. New and emerging treatment approaches to lupus. Biologics 2010;4:263-71.
11. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled phase 3 trial. Lancet 2011;377:721-31.
12. Sthoeger Z, Sharabi A, Mozes E. Novel approaches to the development of targeted therapeutic agents. J Autoimmun 2014;54:60-71.
13. Sthoeger ZM, Dayan M, Tcherniack A, et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA antibodies. Clin Exp Immunol 2003;131:385-92.
14. Shoenfeld Y, Isenberg DA, Rauch J, et al. Idiotypic cross-reactions of monoclonal human lupus autoantibodies. J Exp Med 1983;58:718-30.
15. A, Mozes E, Sharabi. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev 2010;10:22-6.
16. Luger D, Dayan M, Zinger H, et al. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004;24:579-90.
17. Mauermann N, Sthoeger Z, Zinger H, et al. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patient. Clin Exp Immunol 2004;137:513-20.
18. Sharabi A, Zinger H, Zborowsky M, et al. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by upregulating CD4+CD25+ cells and TGF-?. Proc Natl Acad Sci 2006;103:8810-5.
19. Sthoeger Z, Zinger H, Sharabi A, et al. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-? in murine and human systemic lupus erythematosus. PLoS ONE 2013;8: e60394.
20. Sharabi A, Dayan M, Zinger H, et al. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. J Clin Immuno 2010;30:34-44.
21. Sthoeger ZM, Sharabi A, Dayan M, et al. The tolerogenic peptide, hCDR1, down-regulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. Hum Immunol 2009;70:139-45.
22. Sthoeger ZM, Sharabi A, Molad Y, et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide). Immunomodulation of gene expression. J Autoimmunity 2009;33:77-82.
23. Gladman DD, Ibanez D Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;2:288-91.
24. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;7:447-58.
25. Cresswell L, Yee CS, Farewell V, et al. Numerical scoring for the classical BILAG index. Rheumatology (Oxford) 2009;48:1548-52.
26. Luijten KM, Tekstra J, Bijlsma JW, et al. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012;11:326-9.
27. Petri M, Buyon J, Kim Mimi. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-91.
28. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naïve T cells. J Exp Med 2004;199:1401-8.
29. Kang HK, Michaels MA, Berner BR, et al. Very low-dose tolerance with nucleosomal peptide controls lupus and induces potent regulatory T cell subsets. J Immunol 2005;174: 3247-55.
30. Sharabi, A. Haviv H. Zinger, H, et al. Amelioration of murine lupus by a peptide, based on the complimentarity determining region-1 of an auto antibody as compared to dexamethasone: different effects on cytokines and aptosis. Clin Immunol 2006;119:146-55.
31. Anonymous. Guidance for industry-systemic lupus erythematosusdeveloping medical products for treatment. s.l : U.S. Department of Health and Human Services, 2010.